前期研究证实，NF-κB参与T2DM大血管病变发病过程。而核因子E2相关因子2（Nrf2）作为NF-κB信号的上游调控基因，是氧化应激及损伤修复的关键环节之一，且证实具有单核苷酸多态性。据此推测，Nrf2多态性与T2DM大血管病变有相关性。因此本课题围绕此假说对不同人群进行Nrf2多态性分析，首先在数据库下载Nrf2基因SNPs等位基因，筛选出标签SNPs位点，然后对全部位点进行基因分型，并采用聚合酶链反应-限制性片段长度多态性方法检测Nrf2位点多态性。明确其与T2DM大血管病变的关系；并根据前期研究，选用最佳配伍比例芪归药对对T2DM大血管病变患者进行干预，通过分析Nrf2多态性各基因型氧化应激产物8异前列腺素F2α(8-iso-PGF2α)及Nrf2和下游因子的表达，验证Nrf2多态性和氧化应激与T2DM大血管病变的关系。并从氧化应激角度探索益气活血法治疗T2DM大血管病变的有效性。

Our preliminary studies showed that the activation of the NF-kappaB took participate in the occurrence of the T2DM macroangiopathy, Nuclear factor E2 related factor 2 (Nrf2) is one upstream regulatory factor of NF- kappa B and works as a key element in the oxidative stress is the core factor of the T2DM mechanism of vascular disease,And was confirmed with a single nucleotide polymorphism.It is assumed that the Nrf2 gene polymorphism may be related with the T2DM macrovascular disease. Therefore,this project plans to test the polymorphism of the Nrf2 gene in different populations to explore its distribution characters in the different population,first download the Nrf2 gene SNPs allele,screening out the label SNPs sites,then for all loci were genotyped,using polymerase chain reaction restriction fragment length polymorphism method for detecting Nrf2 polymor phis- m,To reveal the relationship between the Nrf2 gene polymorphism and diabetic macroangiopathy. In addition, the patients will be treated with AA herb pairs administrated with the best compatibility proportion. By analyzing the expression of 8-iso-PGF2α(product of oxidative stress)、Nrf2 and its downstream factors,the relationship between the gene polymorphism and diabetic macroangiopathy will be furtherly confirmed. In this way, It is expected to do benefit for screening T2DM patients with high risk of macroangiopathy. Furthermore, from the perspective of oxidative stress,the efficacy of the treatment principle of supplementing Qi and activating blood circulation will be investigated for the patients with T2DM macroangiopathy of qi deficiency and blood stasis syndrome.